Case 1:18-cv-01363-CFC Document 1-4 Filed 09/04/18 Page 1 of 27 PageID #: 252
`Case 1:18-cv-01363-CFC Document1-4
`Filed 09/04/18
`Page 1 of 27 PagelD #: 252
`
`
`
`
`
`
`
`EXHIBIT D
`EXHIBIT D
`
`
`
`

`

`Case 1:18-cv-01363-CFC Document 1-4 Filed 09/04/18 Page 2 of 27 PageID #: 253
`
`US007846441B1
`
`(12) United States Patent
`Hellmann
`
`(io) Patent No.:
`(45) Date of Patent:
`
`US 7,846,441 B1
`Dec. 7, 2010
`
`(54) TREATMENT WITH ANTI-ERBB2
`ANTIBODIES
`
`(75)
`
`Inventor: Susan D. Hellmann, San Carlos, CA
`(US)
`
`(73) Assignee: Genentech, Inc., South San Francisco,
`CA (US)
`
`(*) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`(21) Appl.No.: 09/208,649
`
`(22) Filed:
`
`Dec. 10,1998
`
`Related U.S. Application Data
`(60) Provisional application No. 60/069,346, filed on Dec.
`12, 1997.
`
`(51)
`
`Int. Cl.
`(2006.01)
`A61K 39/395
`(52) U.S. Cl................. 424/143.1; 424/130.1; 424/133.1;
`424/135.1; 424/136.1; 424/141.1; 424/142.1;
`424/152.1; 424/155.1; 424/156.1; 424/172.1;
`424/174.1
`(58) Field of Classification Search .............. 424/137.1,
`424/138.1, 141.1, 227.1, 152.1, 130.1, 133.1,
`424/135.1, 136.1, 142.1, 143.1, 155.1, 156.1,
`424/172.1, 174.1
`See application file for complete search history.
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`4,017,471 A
`4/1977 Davies
`4,753,894 A
`6/1988 Frankel et al.
`4,935,341 A
`6/1990 Bargmann et al.
`4,943,533 A
`7/1990 Mendelsohn et al.
`4,968,603 A
`11/1990 Slamon et al.
`4,975,278 A
`12/1990 Senter et al.
`4,994,558 A
`2/1991 Armour et al.
`5,169,774 A
`12/1992 Frankel et al.
`5,183,884 A
`2/1993 Kraus et al.
`5,288,477 A
`2/1994 Bacus
`5,359,046 A
`10/1994 Capon et al.
`5,367,060 A
`11/1994 Vandlen et al.
`5,401,638 A
`3/1995 Carney et al.
`5,464,751 A
`11/1995 Greene et al.
`5,480,968 A
`1/1996 Kraus et al.
`5,514,554 A
`5/1996 Bacus
`5,571,894 A
`11/1996 Weis et al.
`5,578,482 A
`11/1996 Lippman et al.
`5,587,458 A
`12/1996 King et al.
`5,604,107 A
`2/1997 Carney et al.
`5,641,869 A
`6/1997 Vandlen et al.
`5,663,144 A
`9/1997 Greene et al.
`5,677,171 A
`10/1997 Hudziak et al.
`5,705,157 A
`1/1998 Greene
`5,720,937 A
`2/1998 Hudziak et al.
`5,720,954 A
`2/1998 Hudziak et al.
`5,725,856 A
`3/1998 Hudziak et al.
`5,726,023 A
`3/1998 Cheever et al.
`5,728,687 A
`3/1998 Bissery
`5,747,261 A
`5/1998 King et al.
`
`424/143.1
`
`5,770,195 A
`5,772,997 A
`5,776,427 A
`5,783,186 A *
`5,783,404 A
`5,801,005 A
`5,804,396 A
`5,821,337 A
`5,824,311 A
`5,834,229 A
`5,837,243 A
`5,837,523 A
`5,840,525 A
`5,846,538 A
`5,846,749 A
`5,856,089 A
`5,856,110 A
`5,859,206 A
`5,869,445 A
`5,876,712 A
`5,877,305 A
`5,908,835 A
`5,910,486 A
`5,922,845 A
`5,925,519 A
`5,939,531 A
`5,977,322 A
`
`6/1998 Hudziak et al.
`6/1998 Hudziak et al.
`7/1998 Thorpe et al.
`7/1998 Arakawaetal. ..
`7/1998 Koski
`9/1998 Cheever et al.
`9/1998 Plowman
`10/1998 Carter et al.
`10/1998 Greene et al.
`11/1998 Vandlen et al.
`11/1998 Deo et al.
`11/1998 Greene et al.
`11/1998 Vandlen et al.
`12/1998 Cheever et al.
`12/1998 Slamon et al.
`1/1999 Wang et al.
`1/1999 Vandlen et al.
`1/1999 Vandlen et al.
`2/1999 Cheever et al.
`3/1999 Cheever et al.
`3/1999 Huston et al.
`6/1999 Bissery
`6/1999 Curiel et al.
`7/1999 Deo et al.
`7/1999 Jensen et al.
`8/1999 Weis et al.
`11/1999 Marks et al.
`
`(Continued)
`FOREIGN PATENT DOCUMENTS
`
`EP
`
`599274
`
`6/1994
`
`(Continued)
`OTHER PUBLICATIONS
`
`Seidman et al., Seminars in Oncology, vol. 22, No. 5, Suppl 12, Oct.
`1995, pp. 108-116*
`
`(Continued)
`Primary Examiner—Alana M. Harris
`Assistant Examiner—Anne L Holleran
`(74) Attorney, Agent, or Firm—Ginger R. Dreger; Atulya R.
`Agarwal
`
`(57)
`
`ABSTRACT
`
`The present invention concerns the treatment of disorders
`characterized by the overexpression of ErbB2. More specifi­
`cally, the invention concerns the treatment of human patients
`susceptible to or diagnosed with cancer overexpressing
`ErbB2 with a combination of an anti-ErbB2 antibody and a
`chemotherapeutic agent other than an anthracycline, e.g.
`doxorubicin or epirubicin.
`
`14 Claims, 2 Drawing Sheets
`
`

`

`Case 1:18-cv-01363-CFC Document 1-4 Filed 09/04/18 Page 3 of 27 PageID #: 254
`
`US 7,846,441 B1
`Page 2
`
`U.S. PATENT DOCUMENTS
`King et al.
`Ross et al.
`Hudziak et al.
`Curiel et al.
`Carter et al.
`Ring
`Shawver et al.
`Hudziak et al.
`Benzetal.................... 424/143.1
`Bissery
`Andya et al.
`Deo et al.
`Bishop et al.
`Vogel et al.
`Basey et al.
`Hudziak etal.............. 424/138.1
`Deo et al.
`Hung et al.
`Hudziak et al.
`Carter et al.
`Arakawa et al.
`Marks et al.
`Baughman et al.
`Carter et al.
`Andya et al.
`Carter et al.
`Carter et al.
`Cleland et al.
`Sliwkowski
`Andya et al.
`Erickson et al.
`Andya et al.
`Erickson et al.
`Buchsbaum
`Stuart et al.
`Rockwell et al.
`Rockwell et al.
`Paton et al.
`Hellmann
`Andya et al.
`Bissery
`Paton et al.
`Baughman et al.
`Bossenmaier et al.
`Carter et al.
`Brunetta et al.
`Hellmann
`Adams et al.
`Sliwkowski
`Ashkenazi et al.
`Kelsey
`Kao et al.
`Agus
`Adams et al.
`Adams et al.
`Sliwkowski
`Andya et al.
`Andya et al.
`Amler et al.
`Allison et al.
`Derynck et al.
`Adams et al.
`Adams et al.
`Sliwkowski et al.
`Baughman et al.
`Mass
`Bryant
`Andya et al.
`Sliwkowski et al.
`Ashkenazi et al.
`Moecks et al.
`
`11/1999
`5,985,553 A
`11/1999
`5,994,071 A
`1/2000
`6,015,567 A
`2/2000
`6,028,059 A
`4/2000
`6,054,297 A
`4/2000
`6,054,561 A
`9/2000
`6,123,939 A
`12/2000
`6,165,464 A
`4/2001
`6,214,388 B1 *
`4/2001
`6,214,863 B1
`7/2001
`6,267,958 B1
`8/2001
`6,270,765 B1
`11/2001
`6,316,462 B1
`12/2001
`6,333,348 B1
`1/2002
`6,339,142 B1
`5/2002
`6,387,371 B1 *
`5/2002
`6,395,272 B1
`5/2002
`6,395,712 B1
`6/2002
`6,399,063 B1 *
`6/2002
`6,407,213 B1
`6,458,356 B1 * 10/2002
`6,512,097 B1
`1/2003
`6,627,196 B1
`9/2003
`6,639,055 B1
`10/2003
`6,685,940 B2
`2/2004
`6,719,971 B1
`4/2004
`6,800,738 B1
`10/2004
`6,821,515 B1
`11/2004
`7,041,292 B1
`5/2006
`7,060,268 B2
`6/2006
`7,097,840 B2
`8/2006
`2001/0014326 Al
`8/2001
`2002/0001587 Al
`1/2002
`2002/0076408 Al
`6/2002
`2002/0155527 Al
`10/2002
`2003/0103973 Al
`6/2003
`2003/0108545 Al
`6/2003
`2003/0147884 Al
`8/2003
`2003/0170234 Al
`9/2003
`2003/0202972 Al
`10/2003
`2004/0013660 Al
`1/2004
`2004/0037823 A9
`2/2004
`2004/0037824 Al
`2/2004
`2004/0106161 Al
`6/2004
`2004/0236078 Al
`11/2004
`2004/0258685 Al
`12/2004
`2005/0002928 Al
`1/2005
`2005/0208043 Al
`9/2005
`2005/0238640 Al
`10/2005
`2005/0244417 Al
`11/2005
`2006/0013819 Al
`1/2006
`2006/0018899 Al
`1/2006
`2006/0034840 Al
`2/2006
`2006/0034842 Al
`2/2006
`2006/0073143 Al
`4/2006
`2006/0083739 Al
`4/2006
`2006/0088523 Al
`4/2006
`2006/0099201 Al
`5/2006
`2006/0121044 Al
`6/2006
`2006/0165702 Al
`7/2006
`2006/0188509 Al
`8/2006
`2006/0193854 Al
`8/2006
`2006/0198843 Al
`9/2006
`2006/0204505 Al
`9/2006
`2006/0210561 Al
`9/2006
`2006/0228745 Al
`10/2006
`2006/0275305 Al
`12/2006
`2006/0275306 Al
`12/2006
`2007/0020261 Al
`1/2007
`2007/0026001 Al
`2/2007
`2007/0037228 Al
`2/2007
`
`2007/0166753 Al
`2007/0184055 Al
`2007/0202516 Al
`2007/0224203 Al
`2007/0269429 Al
`2007/0292419 Al
`
`7/2007 Mass
`8/2007 Sliwkowski
`8/2007 Mass
`9/2007 Friess et al.
`11/2007 Kelsey et al.
`12/2007 Hellmann
`
`FOREIGN PATENT DOCUMENTS
`
`EP
`EP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`WO
`WO
`WO
`WO
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`
`0616812 Al
`711565
`95006982 B2
`2761543 B2
`2895105 B2
`3-240498
`5-117165
`5-170667
`5-213775
`5-317084
`7-59588
`WO 87/07646
`WO 89/06692
`WO 89/10412
`WO 91/02062
`WO 91/05264
`WO 92/10573
`WO 93/03741
`WO 93/12220
`WO 93/16185
`WO 93/21232
`WO 93/21319
`WO 94/00136
`WO 94/22478
`WO 94/28127
`WO 95/16051
`WO 95/17507
`WO 95/28485
`WO 96/07321
`WO 96/16673
`WO 96/18409
`WO 96/40789
`WO 97/00271
`WO 97/20858
`WO 97/27848
`WO 97/38731
`WO 98/02463
`WO 98/17797
`WO 98/18489
`WO 98/33914
`WO 98/45479
`WO 99/24401
`WO 99/25320
`WO 99/31140
`WO 00/61145
`WO 00/61185
`WO 00/69460 Al
`WO 01/87334
`WO 02/055106
`WO 2007/145862 A2
`
`9/1994
`8/1998
`5/1987
`6/1990
`8/1991
`10/1991
`5/1993
`7/1993
`8/1993
`12/1993
`3/1995
`12/1987
`7/1989
`11/1989
`2/1991
`4/1991
`6/1992
`3/1993
`6/1993
`8/1993
`10/1993
`10/1993
`1/1994
`10/1994
`12/1994
`6/1995
`6/1995
`10/1995
`3/1996
`6/1996
`6/1996
`12/1996
`1/1997
`6/1997
`8/1997
`10/1997
`1/1998
`4/1998
`5/1998
`8/1998
`10/1998
`5/1999
`5/1999
`6/1999
`10/2000
`10/2000
`11/2000
`11/2001
`7/2002
`12/2007
`
`OTHER PUBLICATIONS
`Davidson, Seimanars in Oncology, vol. 22, No. 6, Suppl. 14, Dec.
`1995, pp. 2-6.*
`van Oosterom, et al. Anti-Cancer Drugs, 6(3): 356-368, 1995;
`Abstract only.*
`Merlin, et al, Annals of Oncology 13: 1743-1748, 2002.*
`Kaye, S.B. et al. European Journal of Cancer 33(13) 2167-2176,
`1997.*
`Grant, D.S., etal, lnt. J. Cancer 104: 121-129, 2003.*
`Nallani, S.C., et al, Cancer Chemother Pharmacol (2004) 54: 219-
`229.*
`Untch, M. et al, Anticancer Drugs, 5(1): 24-30, 1994; abstract only.*
`
`

`

`Case 1:18-cv-01363-CFC Document 1-4 Filed 09/04/18 Page 4 of 27 PageID #: 255
`
`US 7,846,441 B1
`Page 3
`
`The American Heritage Dictionary of the English Language,
`Houghton Mifflin, Chicago, from http://www.credoreference.com/
`entry/4085073 *
`Cottin, Y, et al. Br. Heart Journal, 73: 61-64, 1995.*
`Baselga et al., “Monoclonal antibodies directed against growth factor
`receptors enhance the efficacy of chemotherapeutic agents” Annals of
`Oncology (abstract #010) 5(Suppl. 5) (1994).
`Mendelsohn et al., “Receptor blockade and chemotherapy: a new
`approach to combination cancer therapy” Annals of Oncology
`(abstract #040) 7(Suppl. 1):22 (1996).
`Arteaga et al., “pl85c'eriλS'2 signaling enhances cisplatin-induced
`cytotoxicity in human breast carcinoma cells: association between an
`oncogenic receptor tyrosine kinase and drug-induced DNA repair”
`Cancer Research 54(14):3758-3765 (Jul. 15, 1994).
`Bacus et al., “Differentiation of cultured human breast cancer cells
`(AU-565 andMCF-7) associated with loss of cell surface HER-2/neu
`antigen” Molecular Carcinogenesis 3(6):350-362 (1990).
`Bacus et al., “Tumor-inhibitory monoclonal antibodies to the HER-
`2/Neu receptor induce differentiation of human breast cancer cells”
`Cancer Research 52(9):2580-2589 (May 1, 1992).
`Baselga et al., “Anti HER2 Humanized Monoclonal Antibody (MAb)
`Alone and in Combination with Chemotherapy Against Human
`Breast Carcinoma Xenografts” Proceedings of ASCO-13th Annual
`Meeting (Abstract #53), Dallas, TX 13:63 (Mar. 1994).
`Baselga et al., “HER2 overexpression and paclitaxel sensitivity in
`breast cancer: therapeutic implications” Oncology 11(3 Suppl 2):43-
`48 (Mar. 1997).
`Baselga et al., “Phase 11 Study of Weekly Intravenous Recombinant
`Humanized Anti-plδS^^2 Monoclonal Antibody in Patients With
`HER2/neu-Overexpressing Metastatic Breast Cancer” J. Clin.
`Oncol. 14(3):737-744 (1996).
`Carter et al., “Humanization of an anti-plSS77^2 antibody for human
`cancer therapy” Proc. Natl. Acad. Sci. 89:4285-4289 (1992).
`D’souza et al., “Overexpression of ERBB2 in human mammary
`epithelial cells signals inhibition of transcription of the E-cadherin
`gene” Proc. Natl. Acad. Sci. USA 91(15):7202-7206 (Jul. 19, 1994).
`DiFiore et al., “erbB-2 is a potent oncogene when overexpressed in
`N1H/3T3 cells” Sc/e/7ce237(4811):178-182 (Jul. 10, 1987).
`Drebin et al., “Down-Modulation of and Oncogene Protein Product
`an Reversion of the Transformed Phenotype by Monoclonal Anti­
`bodies” Cell 41(3):695-706 (1985).
`Drebin et al., “Inhibition of tumor growth by a monoclonal antibody
`reactive with an oncogene-encoded tumor antigen” Proc. Natl. Acad.
`Sci. 83:9129-9133 (1986).
`Drebin et al., “Monoclonal antibodies reactive with distinct domains
`of the neu oncogene-encoded pi 85 molecule exert synergistic anti­
`tumor effects in vivo” Oncogene 2:273-277 (1988).
`Drebin et al., “Monoclonal Antibodies Specific for the neu Oncogene
`Product Directly Mediate Anti-tumor Effects In Vivo” Oncogene
`2(4):387-394 (1988).
`Fendly et al., “Characterization of Murine Monoclonal Antibodies
`Reactive to Either the Human Epidermal Growth Factor Receptor or
`HER2/neu Gene Product” Cancer Research 50:1550-1558 (Mar. 1,
`1990).
`Fleiss, JL Statistical Methods for Rates and Proportions, 2nd edition,
`New York, NY;Wiley pp. 13-17 (1981).
`Green et al., “Preclinical Evaluation of WR-151327: An Orally
`Active Chemotherapy Protector” Cancer Research 54(3):738-741
`(Feb. 1, 1994).
`Guy et al., “Expression of the neu protooncogene in the mammary
`epithelium of transgenic mice induces metastatic disease” Proc. Natl.
`Acad. Sci. USA 89(22): 10578-10582 (Nov. 15, 1992).
`Hancock et al., “A Monoclonal Antibody Against the c-erbB-2 Pro­
`tein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum
`Against Human Breast and Ovarian Tumor Cell Lines” Cancer
`Research 51:4575-4580 (Sep. 1, 1991).
`Harwerth et al., “Monoclonal antibodies against the extracellular
`domain of the erbB-2 receptor function as partial ligand agonists”
`Journal of Biological Chemistry 267(21): 15160-15167 (Jul. 1992).
`Hudziak et al., “Increased expression of the putative growth factor
`receptor pi85^^ causes transformation and tumorigenesis of N1H
`3T3 cells” Proc. Natl. Acad. Sci. 84:7159-7163 (1987).
`
`Monoclonal Antibody Has Antiprolifera­
`Hudziak et al.,
`tive Effects In Vitro and Sensitizes Human Breast Tumor Cells to
`Tumor Necrosis Factor” Molecular & Cellular Biology 9(3): 1165-
`1172(1989).
`Hynes and Stern, “The biology of erbB-2/neu/HER-2 and its role in
`cancer”Biochimica etBiophysica Acta 1198(2-3): 165-184 (Dec. 30,
`1994).
`Kasprzyk et al., “Therapy of an animal model of human gastric
`cancer using a combination of anti-erbB-2 monoclonal antibodies”
`Cancer Research 52(10):2771-2776 (May 15, 1992).
`Kotts et al., “Differential growth inhibition of human carcinoma cells
`exposed to monoclonal antibodies directed against the extracellular
`domain of the HER2/ERBB2 protooncogene” In Vitro (Abstract
`#176) 26(3):59A (1990).
`Kumar et al., “Regulation of phosphorylation of the c-erbB-2/HER2
`gene product by a monoclonal antibody and serum growth factor(s) in
`human mammary carcinoma cells” Molecular & Cellular Biology
`11(2):979-986 (Feb. 1991).
`Lewis et al., “Differential Responses of Human Tumor Cell Lines to
`Anti-plδS^^2 Monoclonal Antibodies” Cancer Immunol.
`Immunother. 37:255-263 (1993).
`Maier et al., “Requirements for the internalization of a murine
`monoclonal antibody directed against the HER-2/neu gene product
`c-erbB-2” Cancer Research 51(19): 5361-5369 (Oct. 1, 1991).
`McKenzie et al., “Generation and characterization of monoclonal
`antibodies specific for the human neu oncogene product, pi 85”
`Oncogene 4:543-548 (1989).
`Myers et al., “Biological Effects of Monoclonal Antireceptor Anti­
`bodies Reactive with neu Oncogene Product, pl85”eω” Methods in
`Enzymology 198:277-290 (1991).
`Norton, L, “Evolving concepts in the systemic drug therapy of breast
`cancer” Seminars in Oncology 24(4 Suppl 10):S10-3-S10-10 (Aug.
`1997).
`Pietras et al., “Antibody to HER-2/neu Receptor Blocks DNA Repair
`After Cisplatin in Human Breast and Ovarian Cancer Cells”
`Oncogene 9:1829-1838 (1994).
`Ravdin and Chamness, “The c-erbB-2 proto-oncogene as a prognos­
`tic and predictive marker in breast cancer: a paradigm for the devel­
`opment of other macromolecular markers—a review” Gene
`159(1): 19-27 (Jun. 14, 1995).
`Sarup, “Characterization of an Anti-PlSS77^'2 Monoclonal Anti­
`body that Stimulates Receptor Function and Inhibits Tumor Cell
`Growth” Growth Regulation 1:72-82 (1991).
`Scott et al., “pl85^£Λ2 signal transduction in breast cancer cells”
`Journal of Biological Chemistry 266(22): 14300-14305 (Aug. 5,
`1991).
`Seifert et al., “Dexrazoxane in the prevention of doxorubicin-induced
`cardiotoxicity” Annals of Pharmacotherapy 28(9): 1063-1072 (Sep.
`1994).
`Shawver et al., “Ligand-like effects induced by anti-c-erbB-2 anti­
`bodies do not correlate with and are not required for growth inhibition
`of human carcinoma cells” Cancer Research 54(5): 1367-1373 (Mar.
`1, 1994).
`Shepard et al., “Monoclonal Antibody Therapy of Human Cancer:
`Taking the HER2 Protooncogene to the Clinic” J. Clin. Immunol.
`11(3): 117-127 (1991).
`Singal and lliskovic, “Doxorubicin-induced cardiomyopathy” New
`England J. of Medicine 339(13):900-905 (Sep. 24, 1998).
`Singal et al., “Combination therapy with probucol prevents
`adriamycin-induced cardiomyopathy” Journal of Molecular & Cel­
`lular Cardiology 27(4): 1055-1063 (Apr. 1995).
`Slamon et al., “Human Breast Cancer: Correlation of Relapse and
`Survival with Amplification of the HER-2/neu Oncogene” Science
`235:177-182 (1987).
`Slamon, etal., “Studies of the HER-2/neu Proto-oncogene in Human
`Breast and Ovarian Cancer” Science 244:707-712 (May 1989).
`Sliwkowski et al., “Coexpression of erbB2 and erbB3 proteins recon­
`stitutes a high affinity receptor for heregulin” Journal of Biological
`Chemistry 269(20): 14661-14665 (1994).
`Stancovski et al., “Mechanistic aspects of the opposing effects of
`monoclonal antibodies to the ERBB2 receptor on tumor growth”
`Proc. Natl. Acad. Sci. USA 88(19):8691-8695 (Oct. 1, 1991).
`
`

`

`Case 1:18-cv-01363-CFC Document 1-4 Filed 09/04/18 Page 5 of 27 PageID #: 256
`
`US 7,846,441 B1
`Page 4
`
`Tagliabue et al., “Selection of monoclonal antibodies which induce
`internalization and phosphorylation of p 1 %5HER2 and growth inhibi­
`tion of cells with HER2/NEU gene amplification” International
`Journal of Cancer 47(6):933-937 (Apr. 1, 1991).
`Vitetta et al., “Monoclonal antibodies as agonists: an expanded role
`for their use in cancer therapy” Cancer Research 54(20):5301-5309
`(Oct. 15, 1994).
`Xu et al., “Antibody-induced growth inhibition is mediated through
`immunochemically and functionally distinct epitopes on the
`extracellular domain of the c-erbB-2 (HER- 2/neu) gene product
`International Journal of Cancer 53(3):401-408 (Feb. 1,1993).
`Baselga et al., “Recombinant Humanized Anti-HER2 Antibody
`(Herceptin) Enchances the Antitumor Activity of Paclitaxel and
`Doxorubicin against HER2/neu Overexpessing Human Breast Can­
`cer Xenografts” Cancer Research 58:2825-2831 (Jul. 1998).
`“Herceptin (Trastuzumab)” Product Information (2000).
`Pegram et al., “Inhibitory effects of combinations of HER-2/neu
`antibody and chemotherapeutic agents used for treatment of human
`breast cancers” Oncogene 18:2241-2251 (1999).
`Raefsky et al., “Phase 11 Trial of Docetaxel and Herceptin as First- or
`Second-Line Chemotherapy for Women with Metastatic Breast Can­
`cer Whose Tumors Overexpress HER2” Proceedings of ASCO
`(Abstract #523) 18:137a (1999).
`Baselga et al., “Receptor Blockade With Monoclonal Antibodies As
`Anti-Cancer Therapy” Pharmac. Ther. 64:127-154 (1994).
`De Santes et al., “Radiolabeled Antibody Targeting of the HER-2/neu
`Oncoprotein” Cancer Research 52:1916-1923 (1992).
`llgen et al., “Characterization of anti-HER/2 antibodies which inhibit
`the growth of breast tumor cells in vitro” Proceedings of the Ameri­
`can Association for Cancer Research (abstract #3209) 37:470 (Mar.
`1996).
`Lewis et al., “Growth Regulation of Human Breast and Ovarian
`Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2
`as a Critical Component in Mediating Heregulin Responsiveness”
`Cancer Research 56:1457-1465 (Mar. 15, 1996).
`Masui et al., “Growth Inhibition of Human Tumor Cells in Athymic
`Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Anti­
`bodies” Cancer Research 44(3): 1002-1007 (Mar. 1984).
`Masuko et al., “A murine Monoclonal Antibody That Recognizes an
`Extracellular Domain of the Human c-erbB-2 Protooncogene Prod­
`uct” Jpn J. Cancer Res. 80:10-14 (Jan. 1989).
`McCann etal., “c-erbB-2 Oncoprotein Expression in Primary Human
`Tumors” Cancer 65(l):88-92 (Jan. 1, 1990).
`Rodeck et al., “Interactions between growth factor receptors and
`corresponding monoclonal antibodies in human tumors” J. Cellular
`Biochem. 35(4):315-320 (1987).
`Schlom, J., “Monoclonal Antibodies: They’re More and Less Than
`You Think” Molecular Foundations of Oncology, Broder, S. ed.,
`Baltimore, MD;Williams & Wilkins, Chapter 6, pp. 95-134 (1991).
`Sliwkowski et al., “A humanized monoclonal antibody for the treat­
`ment of HER2 overexpressing breast cancer” Proceedings of the
`American Association for Cancer Research 37:625-626 (Mar. 1996).
`Zhang et al., “Shared antigenic epitopes and pathobiological func­
`tions of anti-pl85Λer2/”eω monoclonal antibodies” Experimental and
`Molecular Pathology 61:15-25 (1999).
`Baselga et al., “Antitumor activity of paclitaxel in combination with
`anti-growth factor receptor monoclonal antibodies in breast cancer
`xenografts” Proceedings of the American Association for Cancer
`Research (Abstract No. 2262) 35:380 (Mar. 1994).
`Baselga et al., “Antitumor effects of doxorubicin in combination with
`anti-epidermal growth factor receptor monoclonal antibodies” Jour­
`nal of the National Cancer Institute 85(16): 1327-1333 (Aug. 18,
`1993).
`Bunn et al., “HER2/neu expression and effects of Herceptin alone
`and in combination with cytotoxic agents in lung cancer” Proceed­
`ings of the American Association for Cancer Research (Abstract No.
`4571) 41:719 (Mar. 2000).
`Carmichael et al., “Advanced breast cancer: a phase 11 trial with
`gemcitabine” Journal of Clinical Oncology 13(11):2731-2736 (Nov.
`1995).
`Carmichael et al., “Advanced breast cancer: investigational role of
`gemcitabine” European Journal of Cancer 33(Suppl. 1):S27-S30
`(Jan. 1997).
`
`Clemons et al., “Review of recent trials of chemotherapy for
`advanced breast cancer: studies excluding taxanes” European Jour­
`nal of Cancer 33( 13):2171-2182 (Nov. 1997).
`Former et al., “Trastuzumab in combination with chemotherapy for
`the treatment of metastatic breast cancer” Seminars in Oncology 27(6
`Suppl 11):38-45 (Dec. 2000).
`Gatzemeier et al., “A randomised phase 11 study of gemcitabine/
`cisplatin alone and with Herceptin in patients with HER2-positive
`non-small cell lung cancer (NSCLC)” (Poster to be presented at the
`2001 ECCO meeting).
`Hansen, H., “Gemcitabine—a review” Annals of Oncology (Abstract
`#05 8 from the 9th NC1-EORTC Symposium on New Drugs in Cancer
`Therapy held in Amsterdam on Mar. 12-15, 1996) 7(Suppl. 1):29
`(1996).
`Konecny et al., “Therapeutic advantage of chemotherapy drugs in
`combination with Herceptin against human breast cancer cells with
`HER-2/NEU overexpression” Breast Cancer Res Treat (Abstract No.
`467)57:114(1999).
`Llombart et al., “Biweekly gemcitabine and paclitaxel in advanced
`breast cancer. Phase 11 trial and predictive value of HER2 extracel­
`lular domain (ECD)” European Journal of Cancer (Abstract No.
`390) 36(Suppl 5):S121-S122 (Sep. 2000).
`Miller et al., “Gemcitabine, paclitaxel, and trastuzumab in metastatic
`breast cancer” Oncology 15(2 Supp 3):38-40 (Feb. 2001).
`Mosconi et al., “Combination therapy with gemcitabine in non-small
`cell lung cancer” European Journal of Cancer 33 (Suppl. 1):S14-S17
`(Jan. 1997).
`Nagourney et al., “Trastuzumab (Herceptin) enhancement of
`cytotoxic drug activity in human tumor primary cultures” Breast
`Cancer Res Treat (Abstract No. 475) 57:116 (1999).
`Nelson and Fry, “Inhibition of ERBB family receptors by Cl-1033
`enhances the cytotoxicity of gemcitabine via modulation of AKT and
`map kinases” Proceedings of the American Association for Cancer
`Research (Abstract No. 1533) 41:241 (Mar. 2000).
`Safran et al., “Herceptin and gemcitabine for metastatic pancreatic
`cancers that overexpress HER-2/neu” Proc. Am. Soc. Clin. Oncol.
`(Abstract No. 517) 20:130A (2001).
`Tsai et al., “Cytotoxic effects of gemcitabine-containing regimens
`against human non-small cell lung cancer cell lines which express
`different levels of pl85neu” Cancer Research 56(4):794-801 (Feb. 15,
`1996).
`van Moorsel et al., “Combination chemotherapy studies with
`gemcitabine” Seminars in Oncology 24(2 Suppl. 7):S7-17-S7-23
`(Apr. 1997).
`Zinner et al., “Cisplatin and gemcitabine combined with Herceptin in
`patients (Pts) with HER2 overexpressing, untreated, advanced, non-
`small-cell lung cancer (NSCLC); a phase 11 trial” Proc. Am. Clin.
`Oncol. (Abstract No. 1307) 20:328A (2001).
`Gemzar (gemcitabine HCL), “Product Information—PDR” (2000).
`“Are adjuvant Herceptin trials using the wrong drugs?” Serip
`2493:21 (Nov. 26, 1999).
`Burris et al., “Phase 11 trial of docetaxel and Herceptin(R) as first- or
`second-line chemotherapy for women with metastatic breast cancer
`whose tumours overexpress HER2” European Journal of Cancer
`(Abstract No. 1293) 35(4):3322 (Sep. 1999).
`Albanell et al., “Trastuzumab, a humanized anti-HER2 monoclonal
`antibody, for the treatment of breast cancer” Drugs of Today
`35(12):931-946 (1999).
`“Aminoglutethimide” Martindale—The
`Complete Drug
`Reference—Monographs (website version of product information)
`pp. 1-4(2003).
`Argiris and DiGiovanna, “Synergistic interactions between
`tamoxifen and Herceptin TM” Proceedings of the American Asso­
`ciation for Cancer Research (Abstract #4565) 41:718 (Mar. 2000).
`“Arimidex (anastrozole) Tablets” Physicians' Desk Reference
`(website version of product information) pp. 1-14 (2003).
`“Aromasin (exemestane tablets)” Physicians' Desk Reference
`(website version of product information) pp. 1-9 (2003).
`Benz et al., “Estrogen-dependent, tamoxifen-resistant tumorigenic
`growth of MCF-7 cells transfected with HER2/neu” Breast Cancer
`Research & Treatment 24(2):85-95 (1992).
`
`

`

`Case 1:18-cv-01363-CFC Document 1-4 Filed 09/04/18 Page 6 of 27 PageID #: 257
`
`US 7,846,441 B1
`Page 5
`
`Brueggemeier, R., “Aromatase, aromatase inhibitors, and breast can­
`cer” American Journal of Therapeutics 8(5):333-344 (Sep.-Oct.
`2001).
`“A concerted attack on cancer” Scrip Magazine 2617 (Review Issue
`2000):68-70 (Feb. 14, 2001).
`Dati et al., “Inhibition of c-erbB-2 oncogene expression by estrogens
`in human breast cancer cells” Oncogene 5(7): 1001-1006 (Jul. 1990).
`“Femara (letrozole tablets)” Physicians' Desk Reference (website
`version of product information) pp. 1-13 (2003).
`Grem et al., “A phase 11 evaluation of combination chemotherapy
`plus aminoglutethimide in women with metastatic or recurrent breast
`carcinoma. An Eastern Cooperative Oncology Group Pilot Study”
`American Journal of Clinical Oncology ll(5):528-534 (Oct. 1988).
`Hamilton and Piccart, “The contribution of molecular markers to the
`prediction of response in the treatment of breast cancer: a review of
`the literature on HER-2, p53 and BCL-2” Annals of Oncology
`11(6):647-663 (Jun. 2000).
`Kaufmann et al., “Exemestane is superior to megestrol acetate after
`tamoxifen failure in postmenopausal women with advanced breast
`cancer: Results of a phase 111 randomized double-blind trial” Journal
`of Clinical Oncology 18(7): 1399-1411 (Apr. 2000).
`Konecnyetal., “New drugs in breast cancer therapy: Current position
`and future perspectives” Gynaekologisch-Geburtshilfliche
`Rundschau (English language abstract only) 37(2):54-61 (Oct.
`1997).
`Kunisue et al., “Anti-HER2 antibody enhances the growth inhibitory
`effect of anti-oestrogen on breast cancer cells expressing both
`oestrogen receptors and HER2” British Journal of Cancer 82(1):46-
`51 (Jan. 2000).
`Leyland-Jones et al., “Phase 111 comparative study of trastuzumab
`and paclitaxel with and without carboplatin in patients with HER-2/
`neu positive advanced breast cancer” (Abstract #35. Presented at the
`2002 SABCS meeting.) (2002).
`Lohrisch and Piccart, “Breast cancer: new aspects of adjuvant hor­
`monal therapy” Annals of Oncology ll(Suppl. 3): 13-25 (2000).
`Miller et al., “Phase 11 study of gemcitabine, paclitaxel and
`trastuzumab in metastatic breast cancer; a Hoosier Oncology Group
`trial” (Abstract #437. Presented at the 2002 SABCS meeting.)
`(2002).
`Mizukami et al., “Effects of tamoxifen, medroxyprogesterone acetate
`and estradiol on tumor growth and oncogene expression in MCF-7
`breast cancer cell line transplanted into nude mice” Anticancer
`Research 11(3): 1333-1338 (May-Jun. 1991).
`Pegram et al., “Effect of erbB-2 (HER-2/neu) overexpression on
`chemotherapeutic drug sensitivity in human breast and ovarian can­
`cer cells” Proceedings of the American Association for Cancer
`Research (Abstract No. 152) 34:26 (Mar. 1993).
`Piccart and Kaufmann, “Introduction” European Journal of Cancer
`37(Suppl. 1):S1-S2 (Jan. 2001).
`Piccart et al., “HER2: a ‘predictive factor’ ready to use in the daily
`management of breast cancer patients?” European Journal of Cancer
`36(14): 1755-1761 (Sep. 2000).
`Piccart, M., “Closing remarks and treatment guidelines” European
`Journal of Cancer 37(Suppl. 1):S30-S33 (Jan. 2001).
`Pietras et al., “HER-2 tyrosine kinase pathway targets estrogen recep­
`tor and promotes hormone-independent growth in human breast can­
`cer cells” Oncogene 10(12):2435-2446 (Jun. 15, 1995).
`Pietras et al., “Heregulin promotes growth of human breast cancer
`cells with HER-2 (erb B2) recptors” Proceedings of the American
`Association for Cancer Research (Abstract No. 573) 34:96 (Mar.
`1993).
`Read et al., “Hormonal modulation of HER-2/neu protooncogene
`messenger ribonucleic acid and pi85 protein expression in human
`breast cancer cell lines” Cancer Research 50(13):3947-3951 (Jul. 1,
`1990).
`Warri et al., “Estrogen suppression of erbB2 expression is associated
`with increased growth rate of ZR-75-1 human breast cancer cells in
`vitro and in nude mice” International Journal of Cancer 49(4):616-
`623 (Oct. 21, 1991).
`Witters et al., “Enhanced anti-proliferative activity of the combina­
`tion of tamoxifen plus HER-2-neu antibody” Breast Cancer
`Research & Treatment 42(l):l-5 (Jan. 1997).
`
`Yardley et al., “Final results of the Minnie Pearl Cancer Research
`Network first-line trial of weekly paclitaxel/carboplatin/trastuzumab
`in metastatic breast cancer” (Abstract #439. Presented at the 2002
`SABCS meeting.) (2002).
`Buzdar et al., “Anastrozole, a potent and selective aromatase inhibi­
`tor, versus megestrol acetate in postmenopausal women with
`advanced breast cancer: results of overview analysis of two phase 111
`trials” Journal of Clinical Oncology 14(7):2000-2011 (Jul. 1996).
`Buzdar et al., “Fadrozole HCL (CGS-16949A) versus megestrol
`acetate treatment of postmenopausal patients with metastatic breast
`carcinoma: results of two randomized double blind controlled
`multiinstitutional trials” Cancer 77(12):2503-2513 (Jun. 15, 1996).
`Dickman, S., “Antibodies stage a comeback in cancer treatment”
`Science 280(5367): 1196-1197 (May 22, 1998).
`Kim et al., “Both the epitope specificity and isotype are important in
`the antitumor effect of monoclonal antibodies against Her-2/neu
`antigen” International Journal of Cancer 102(4):428-434 (Dec. 1,
`2002).
`Klijn et al., “Clinical breast cancer, new developments in selection
`and endocrine treatment of patients” Journal of Steroid Biochemistry
`& Molecular Biology 43(1-3) :211 -221 (Sep. 1992).
`Nabholtz et al., “Results of 2 open label multicentre phase 11 pilot
`studies with Herceptin in combination with docetaxel & platinum
`salts (Cis or Carboplatin) (TCH) as therapy for advanced breast
`cancer in women with tumors over-expressing the HER2-neu” Eur. J.
`Cancer (Abst 695) 37(Sup 6):S190 (2001).
`Nabholtz et al., “Results of two open-label multicentre pilot phase 11
`trials with Herceptin in combination with docetaxel and platinum
`salts (Cis or Carboplatin) (TCH) as therapy for advanced breast
`cancer in women overexpressing HER2” Breast Cancer Research
`and Treatment (Abstract #327) 64(1):82 (2000).
`Santen and Harvey, “Use of aromatase inhibitors in breast carci­
`noma” Endocrine-Related Cancer 6(l):75-92 (Mar. 1999).
`Agus et al., “Clinical Activity in a Phase 1 Trial of HER-2-Targeted
`rhuMAb 2C4 (pertuzumab) in Patients with Advanced Solid malig­
`nancies (AST)” Proceedings of the American Association for Cancer
`Research (AbstractNo. 771) 22:192 (2003).
`Agus et al., “Clinical Activity in a Phase 1 Trial of HER2-Targeted
`rhuMAb 2C4 (pertuzumab) in Patients with Advanced Solid Malig­
`nancies” (Slides presented at the 2003 ASCO Annual Meeting) pp.
`1-32 (2003).
`Gordon et al., “Clinical activity of pertuzumab (rhuMab 2C4) in
`advanced, refractory or recurrent ovarian cancer (OC), and the role of
`HER2 activation status” Journal of Clinical Oncology (Abstract
`#5051 from the 41st Annual Meeting ofASCO)23(16S):467s (Jun. 1,
`2005).
`Gordon et al., “Clinical activity of pertuzumab (rhuMab 2C4) in
`advanced, refractory or recurrent ovarian cancer and the role of
`HER2 activation status” (Poster #5051 from the 41st Annual Meeting
`of the American Society of Clinical Oncology (ASCO)) (May 15,
`2005).
`Herzig and Herzig, “Medical Oncology” (website link: http://www.
`qualitysurgical.org/Chapter%2033.htm) pp. 1-11 (2006).
`Hirsh et al., “Preclinical studies of gemcitabine and trastuzumab in
`breast and lung cancer cell lines” Clinical Breast Cancer (abstract
`only) 3(Suppl 1): 12-16 (May 2002).
`O’Shaughnessy et al., “Phase 11 trial of gemcitabine plus trastuzumab
`in metastatic breast cancer patients previously treated with chemo­
`therapy: preliminary results” Clinical Breast Cancer (abstract only)
`3(Suppl 1): 17-20 (May 2002).
`Perez and Hartmann, “Paclitaxel and carboplatin for advanced breast
`cancer” Seminars in Oncology 23(5 Suppl 11):41-45 (Oct. 1